Lack of Efficacy of Suvorexant in People with Insomnia and Poorly Controlled Type 2 Diabetes

References

• Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–111. doi:10.2991/jegh.k.191028.001
   PubMed Web of Science ®Google Scholar
• Khandelwal D, Dutta D, Chittawar S, Kalra S. Sleep disorders in type 2 diabetes. Indian J Endocrinol Metab. 2017;21(5):758–761. doi:10.4103/ijem.IJEM_156_17
   PubMedGoogle Scholar
• Garg H. Role of optimum diagnosis and treatment of insomnia in patients with hypertension and diabetes: a review. J Family Med Prim Care. 2018;7(5):876–883. doi:10.4103/jfmpc.jfmpc_337_17
   PubMedGoogle Scholar
• Schipper SBJ, Van Veen MM, Elders PJM, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia. 2021;64(11):2367–2377. doi:10.1007/s00125-021-05541-0
   PubMed Web of Science ®Google Scholar
• Knutson KL. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Archives of Internal Medicine. 2006;166(16):1768–1774. doi:10.1001/archinte.166.16.1768
   PubMed Web of Science ®Google Scholar
• Koopman ADM, Beulens JW, Dijkstra T, et al. Prevalence of insomnia (symptoms) in T2D and association with metabolic parameters and glycemic control: meta-analysis. J Clin Endocrinol Metab. 2019;105(3):614–643. doi:10.1210/clinem/dgz065
   Web of Science ®Google Scholar
• Lee SWH, Ng KY, Chin WK. The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis. Sleep Med Rev. 2017;31:91–101. doi:10.1016/j.smrv.2016.02.001
   PubMed Web of Science ®Google Scholar
• Knutson KL, Van Cauter E, Zee P, Liu K, Lauderdale DS. cross-sectional associations between measures of sleep and markers of glucose metabolism among subjects with and without diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Sleep Study. Diabetes Care. 2011;34(5):1171–1176. doi:10.2337/dc10-1962
   PubMed Web of Science ®Google Scholar
• Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 2022. doi:10.1056/NEJM199309303291401
   Google Scholar
• UK prospective diabetes study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865. doi:10.1016/S0140-6736(98)07037-8
   PubMed Web of Science ®Google Scholar
• UK prospective diabetes study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. doi:10.1016/S0140-6736(98)07019-6
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. doi:10.1056/NEJMoa0806470
   PubMed Web of Science ®Google Scholar
• García-Serrano C, Pujol Salud J, Aran-Solé L, et al. Enhancing night and day circadian contrast through sleep education in prediabetes and type 2 diabetes mellitus: a randomized controlled trial. Biology. 2022;11(6):893. doi:10.3390/biology11060893
   PubMedGoogle Scholar
• Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. 2011;4:307–313. doi:10.2147/DMSO.S23904
   PubMedGoogle Scholar
• Tsunoda T, Yamada M, Akiyama T, et al. The effects of ramelteon on glucose metabolism and sleep quality in type 2 diabetic patients with insomnia: a pilot prospective randomized controlled trial. J Clin Med Res. 2016;8(12):878–887. doi:10.14740/jocmr2754w
   PubMedGoogle Scholar
• Winkelman JW. Insomnia disorder. N Engl J Med. 2015;373(15):1437–1444. doi:10.1056/NEJMcp1412740
   PubMed Web of Science ®Google Scholar
• Tan X, van Egmond L, Chapman CD, Cedernaes J, Benedict C. Aiding sleep in type 2 diabetes: therapeutic considerations. Lancet Diabetes Endocrinol. 2018;6(1):60–68. doi:10.1016/S2213-8587(17)30233-4
   PubMed Web of Science ®Google Scholar
• Herring WJ, Connor KM, Snyder E, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized Controlled clinical trials. J Clin Sleep Med. 2016;12(09):1215–1225. doi:10.5664/jcsm.6116
   PubMedGoogle Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–585. doi:10.1016/s0092-8674(00)80949-6
   PubMed Web of Science ®Google Scholar
• Tsuneki H, Wada T, Sasaoka T. Role of orexin in the central regulation of glucose and energy homeostasis. Endocr J. 2012;59(5):365–374. doi:10.1507/endocrj.ej12-0030
   PubMed Web of Science ®Google Scholar
• Tsuneki H, Kon K, Ito H, et al. Timed inhibition of orexin system by suvorexant improved sleep and glucose metabolism in type 2 diabetic db/db mice. Endocrinology. 2016;157(11):4146–4157. doi:10.1210/en.2016-1404
   PubMed Web of Science ®Google Scholar
• Rines AK, Sharabi K, Tavares CDJ, Puigserver P. Targeting hepatic glucose output in the treatment of type 2 diabetes. Nat Rev Drug Discov. 2016;15(11):786–804. doi:10.1038/nrd.2016.151
   PubMed Web of Science ®Google Scholar
• Toi N, Inaba M, Kurajoh M, et al. Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus. J Clin Transl Endocrinol. 2018;15:37–44. doi:10.1016/j.jcte.2018.12.006
   PubMedGoogle Scholar
• Yoshikawa F, Shigiyama F, Ando Y, et al. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia. Diabetes Res Clin Pract. 2020;169:108412. doi:10.1016/j.diabres.2020.108412
   PubMed Web of Science ®Google Scholar
• Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. PPS. 2003;72(3):115–127. doi:10.1159/000069738
   Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.
   PubMed Web of Science ®Google Scholar
• Morin CM, Belleville G, Bélanger L, Ivers H. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601–608. doi:10.1093/sleep/34.5.601
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi:10.1016/0165-1781(89)90047-4
   PubMed Web of Science ®Google Scholar
• Snyder ES, Tao P, Svetnik V, Lines C, Herring WJ. Use of the single-item patient global impression-severity scale as a self-reported assessment of insomnia severity. J Sleep Res. 2021;30(1):e13141. doi:10.1111/jsr.13141
   PubMed Web of Science ®Google Scholar
• Berk M, Ng F, Dodd S, et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract. 2008;14(6):979–983. doi:10.1111/j.1365-2753.2007.00921.x
   PubMed Web of Science ®Google Scholar
• Shen W, Kotsanos JG, Huster WJ, Mathias SD, Andrejasich CM, Patrick DL. Development and validation of the diabetes quality of life clinical trial questionnaire. Med Care. 1999;37(4):AS45–AS66. doi:10.1097/00005650-199904001-00008
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626–631. doi:10.2337/diacare.28.3.626
   PubMed Web of Science ®Google Scholar
• Jackson-Koku G. Beck depression inventory. Occup Med. 2016;66(2):174–175. doi:10.1093/occmed/kqv087
   Google Scholar
• Chen YF, Yang Y, Hung HMJ, Wang SJ. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin Trials. 2011;32(4):592–604. doi:10.1016/j.cct.2011.04.006
   PubMed Web of Science ®Google Scholar
• Bennett DA. How can I deal with missing data in my study? Aust N Z J Public Health. 2001;25(5):464–469. doi:10.1111/j.1467-842X.2001.tb00294.x
   PubMed Web of Science ®Google Scholar
• Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136–148. doi:10.1016/j.biopsych.2014.10.003
   PubMed Web of Science ®Google Scholar
• Florkowski C. HbA1c as a diagnostic test for diabetes mellitus – reviewing the evidence. Clin Biochem Rev. 2013;34(2):75–83.
   PubMedGoogle Scholar
• Buxton OM, Pavlova MK, O’Connor SP, Wang W, Winkelman JW. Lack of change in glucose metabolism in eszopiclone-treated primary insomnia patients. Nat Sci Sleep. 2017;9:187–198. doi:10.2147/NSS.S130505
   PubMed Web of Science ®Google Scholar
• Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. Improving sleep quality leads to better mental health: a meta-analysis of randomised controlled trials. Sleep Med Rev. 2021;60:101556. doi:10.1016/j.smrv.2021.101556
   PubMed Web of Science ®Google Scholar
• Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012;142(Suppl):S8–21. doi:10.1016/S0165-0327(12)70004-6
   PubMed Web of Science ®Google Scholar